secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2024-01-22T23:59:59+00:00
Accession:  0001140361-24-002995
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis announces positive Phase 3 results for donidalorsen in HAE; NDA submission planned
--------------------------------------------------------------------------------

- Donidalorsen met primary endpoint: significant reduction in HAE attack rate for Q4W (p<0.001) and Q8W (p=0.004) vs placebo.
- Favorable safety profile; no serious adverse events in donidalorsen-treated patients.
- Ionis preparing NDA submission to U.S. FDA; Otsuka preparing MAA to European Medicines Agency.
- Third positive Phase 3 readout in 12 months, underscoring LICA platform strength.
- Over 90% of OASIS-HAE patients completed and entered OASIS-Plus open-label extension study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036124002995/0001140361-24-002995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036124002995/ef20019323_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-002995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer